Clinical Trial Update: Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 trial of UK-500,001 for chronic obstructive pulmonary disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• UK-500,001

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: TERMINATED